PATTERNS OF MEDICINE USE FOR COVID-19 PATIENTS AT UNDATA HOSPITAL PALU
Background: Covid-19 cases had drastically increased. Little therapy has been formulated to respond to the situation. Covid-19 symptoms in Indonesia are divided into four classes: asymptomatic, mild, moderate, and severe.
Aims: This study aims to illustrate the pattern of drug use in Covid-19 patients at Undata Palu Hospital.
Methods: This study is a type of cross-sectional descriptive study using a cross-sectional design and collecting data retrospectively from medical records at Undata Hospital Palu in 2020.
Results: In 2020, 186 patients were confirmed positive for Covid-19. There were 95 female patients (51.9%) and 50 patients at the age of 46-55 years (27.3%). The severe symptoms happened to 109 patients (59.6%). The most common clinical manifestation was cough in 127 patients (23.3%). The most common comorbidity was pneumonia (30.8%). The most widely used primary therapy was the antibiotic azithromycin applied to 155 patients (30.0%), and the most widely used supportive therapy was vitamin C among 141 patients (20.1%). Oseltamivir antiviral therapy was administered to 132 patients (25.6%) and remdesivir to 34 patients (6.6%).
Conclusion: Covid-19 patients were mostly treated with antibiotic therapy (41.5%), antiviral therapy (32.2%), antimalarial therapy (15.7%), and corticosteroid therapy (10.7%). As many as 132 patients took oseltamivir, and 34 patients took remdesivir. However, for now, oseltamivir is no longer used.
Bacharier, L.B. et al. (2015) ‘Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial', JAMA, 314(19), pp. 2034–2044. doi:10.1001/jama.2015.13896.
Bosseboeuf, E. et al. (2018) ‘Azithromycin Inhibits the Replication of Zika Virus', Journal of Antivirals & Antiretrovirals, 10(1). doi:10.4172/1948-5964.1000173.
Burhan, E. et al. (2020) Pedoman Tatalaksana COVID-19. 3rd edn. Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). Available at: https://www.papdi.or.id/pdfs/983/Buku%20Pedoman%20Tatalaksana%20COVID-19%205OP%20Edisi%203%202020.pdf.
Carr, A.C. and Maggini, S. (2017) ‘Vitamin C and Immune Function', Nutrients, 9(11), p. 1211. doi:10.3390/nu9111211.
Central Sulawesi Provincial Health Office (2021) Covid-19 situation. March 8, 2021. Palu. Available at: https://dinkes.sultengprov.go.id/update-08-maret-2021/. (Accessed: 8 September 2021).
Chairani, I. (2020) ‘Dampak Pandemi Covid-19 dalam Perspektif Gender di Indonesia', Jurnal Kependudukan Indonesia, p. 39. doi:10.14203/jki.v0i0.571.
Chan, C. (2022) ‘NIH, IDSA update COVID-19 treatment guidelines as Omicron makes comeback', Pharmacy Today, 28(5), pp. 22–23. doi:10.1016/j.ptdy.2022.04.006.
Chen, C. et al. (2020) Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. preprint. Infectious Diseases (except HIV/AIDS). doi:10.1101/2020.03.17.20037432.
Choy, K.-T. et al. (2020) ‘Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro', Antiviral Research, 178, p. 104786. doi:10.1016/j.antiviral.2020.104786.
Darwis, A., Juliandi, J. and Derhana, S. (2021) ‘Penerapan Pendidikan Karakter Di Madrasah Aliyah Yayasan Ittihadiyah Kecamatan Medan Johor Kotamadya Medan', Al-Ulum: Jurnal Pendidikan Islam, 2(3). doi:10.56114/al-ulum.v2i3.165.
Dwipoerwantoro, P.G., Hegar, B. and Witjaksono, P.A.W. (2016) ‘Pola Tata laksana Diare Akut di Beberapa Rumah Sakit Swasta di Jakarta; apakah sesuai dengan protokol WHO?', Sari Pediatri, 6(4), p. 182. doi:10.14238/sp6.4.2005.182-7.
Hairunisa, N. and Amalia, H. (2020) ‘Review: penyakit virus corona baru 2019 (COVID-19)', Jurnal Biomedika dan Kesehatan, 3(2), pp. 90–100. doi:10.18051/jbiomedkes.2020.v3.90-100.
Hayya, A.W. (2021) ‘Penggunaan Klorokuin pada Infeksi Virus COVID-19', Jurnal Inovasi Penelitian, 1(8).
Indonesian Lung Doctors Association (2021) Clinical Practice Guide: Pneumonia 2019-nCoV. Jakarta: PDPI.
Indonesian Ministry of Health (2021) Latest Situation of the Development of Coronavirus Disease (Covid-19). Indonesian Ministry of Health. Available at: https://infectionemerging.kemkes.go.id/situasi-infection-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-09-maret-2021. (Accessed: 10 March 2021).
Liang, H. and Acharya, G. (2020) ‘Novel corona virus disease (COVID"19) in pregnancy: What clinical recommendations to follow?', Acta Obstetricia et Gynecologica Scandinavica, 99(4), pp. 439–442. doi:10.1111/aogs.13836.
Manabe, T. et al. (2021) ‘Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis', BMC Infectious Diseases, 21(1), p. 489. doi:10.1186/s12879-021-06164-x.
Marzuki, I. et al. (2021) COVID-19: Seribu Satu Wajah. Medan: Our Writing Foundation.
Metlay, J.P. and Waterer, G.W. (2020) ‘Treatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic', Annals of internal medicine. 2020/05/07 edn, 173(4), pp. 304–305. doi:10.7326/M20-2189.
Mona, N. (2020) ‘Konsep Isolasi Dalam Jaringan Sosial Untuk Meminimalisasi Efek Contagious (Kasus Penyebaran Virus Corona Di Indonesia)', Jurnal Sosial Humaniora Terapan, 2(2). doi:10.7454/jsht.v2i2.86.
RECOVERY Collaborative Group et al. (2021) ‘Dexamethasone in Hospitalized Patients with Covid-19', The New England journal of medicine. 2020/07/17 edn, 384(8), pp. 693–704. doi:10.1056/NEJMoa2021436.
Rusdi, M.S. (2021) ‘Mini Review: Farmakologi pada Corona Virus Disease (Covid-19)', Lumbung Farmasi: Jurnal Ilmu Kefarmasian, 2(1). doi:https://doi.org/10.31764/lf.v2i1.3974.
Russell, C.D., Millar, J.E. and Baillie, J.K. (2020) ‘Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury', Lancet (London, England). 2020/02/07 edn, 395(10223), pp. 473–475. doi:10.1016/S0140-6736(20)30317-2.
Setiadi, A.P. et al. (2020) ‘Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif', Indonesian Journal of Clinical Pharmacy, 9(1), p. 70. doi:10.15416/ijcp.2020.9.1.70.
Siahaan, M. (2020) ‘Dampak Pandemi Covid-19 Terhadap Dunia Pendidikan', Jurnal Kajian Ilmiah, 1(1), pp. 73–80. doi:10.31599/jki.v1i1.265.
Siahaan, Y.M.T. (2020) ‘Ultrasound Guided Botulinum Toxin-A Injection For Recurrent Piriformis Syndrome: Case Series', Majalah Kedokteran Neurosains Perhimpunan Dokter Spesialis Saraf Indonesia, 37(4). doi:10.52386/neurona.v37i4.178.
Styawan, D.A. (2021) ‘Pandemi COVID-19 Dalam Perspektif Demografi', Seminar Nasional Official Statistics, 2020(1), pp. 182–189. doi: 10.34123/semnasoffstat.v2020i1.716
Tran, D.H. et al. (2019) ‘Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process', The Journal of Antibiotics, 72(10), pp. 759–768. doi:10.1038/s41429-019-0204-x.
Uyeki, T.M. (2018) ‘Oseltamivir Treatment of Influenza in Children', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 66(10), pp. 1501–1503. doi:10.1093/cid/cix1150.
Vermonte, P. and Wicaksono, T.Y. (2020) Karakteristik dan Persebaran COVID-19 di Indonesia: Temuan Awal. CSIS Commentaries DMRU-043-ID. Jakarta: CSIS Indonesia. Available at: https://www.csis.or.id/download/236-post-2020-04-09-CSIS_Commentaries_DMRU_043_ID_VermonteWicaksono.pdf.
Wang, M. et al. (2020) ‘Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro', Cell research. 2020/02/04 edn, 30(3), pp. 269–271. doi:10.1038/s41422-020-0282-0.
Wenham, C. et al. (2020) ‘COVID-19: the gendered impacts of the outbreak', Lancet (London, England). 2020/03/06 edn, 395(10227), pp. 846–848. doi:10.1016/S0140-6736(20)30526-2.
Wibisono, Y. (2003) ‘Konvergensi di Indonesia, Beberapa Temuan Awal dan Implikasinya', Jurnal Ekonomi dan Pembangunan Indonesia, 3(2), pp. 139–153. doi: 10.21002/jepi.v3i2.622.
Widayanto, M.T. (2021) ‘Sosialisasi Pembuatan Pokak Jahe Untuk Meningkatkan Imunitas Dimasa Pandemi Covid-19 di Sumberkedawung Leces Probolinggo', Dharma: Jurnal Pengabdian Masyarakat, 1(2), pp. 93–110. doi:10.35309/dharma.v1i2.4531.
Winugroho, T. et al. (2021) ‘Analisis Pengaruh Faktor Demografi terhadap Lama Karantina pada Perawat Terpapar Covid-19 di Jawa Tengah', PENDIPA Journal of Science Education, 5(2), pp. 229–236. doi:10.33369/pendipa.5.2.229-236.
Wu, Y.-C., Chen, C.-S. and Chan, Y.-J. (2020) ‘The outbreak of COVID-19: An overview', Journal of the Chinese Medical Association : JCMA, 83(3), pp. 217–220. doi: 10.1097/JCMA.0000000000000270.
Xu, X. and Joyce, R. (2020) Sector shutdowns during the coronavirus crisis: which workers are most exposed? 9781912805686. Institute for Fiscal Studies. doi:10.1920/bn.ifs.2020.bn0278.
Zhang, Y. et al. (2019) ‘Effects of macrolides on airway microbiome and cytokine of children with bronchiolitis: A systematic review and meta"analysis of randomized controlled trials', Microbiology and Immunology, 63(9), pp. 343–349. doi:10.1111/1348-0421.12726.
Zhang, Y. et al. (2020) ‘A Novel Coronavirus (COVID-19) Outbreak: A Call for Action', Chest. 2020/02/19 edn, 157(4), pp. e99–e101. doi:10.1016/j.chest.2020.02.014.
Zimmermann, P. et al. (2018) ‘The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms', Frontiers in immunology, 9, pp. 302–302. doi:10.3389/fimmu.2018.00302.
Copyright (c) 2022 Desti Sulistiani Arbi, Amelia Rumi, Nurul Ambianti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use.
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JAKI;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
